BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $19,530.79 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 877 shares of the business's stock in a transaction on Monday, July 7th. The shares were sold at an average price of $22.27, for a total transaction of $19,530.79. Following the sale, the chief financial officer directly owned 185,808 shares in the company, valued at approximately $4,137,944.16. This trade represents a 0.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, June 10th, Troy Wichterman sold 1,042 shares of BioLife Solutions stock. The shares were sold at an average price of $23.70, for a total transaction of $24,695.40.
• On Wednesday, May 28th, Troy Wichterman sold 583 shares of BioLife Solutions stock. The shares were sold at an average price of $22.46, for a total transaction of $13,094.18.

BioLife Solutions Stock Up 3.2%

BioLife Solutions stock traded up $0.73 during mid-day trading on Thursday, hitting $23.06. 108,173 shares of the company's stock were exchanged, compared to its average volume of 419,848. The company has a current ratio of 4.73, a quick ratio of 3.74 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.10 billion, a P/E ratio of -79.58 and a beta of 1.79. BioLife Solutions, Inc. has a 1-year low of $18.70 and a 1-year high of $29.55. The stock has a 50 day moving average of $22.42 and a two-hundred day moving average of $24.39.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.07. The company had revenue of $23.94 million for the quarter, compared to the consensus estimate of $22.22 million. BioLife Solutions had a negative return on equity of 0.66% and a negative net margin of 11.81%. As a group, analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On BioLife Solutions

Several hedge funds have recently made changes to their positions in BLFS. Steward Partners Investment Advisory LLC bought a new stake in shares of BioLife Solutions in the fourth quarter valued at about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioLife Solutions in the fourth quarter valued at about $31,000. State of Wyoming lifted its stake in shares of BioLife Solutions by 353.1% in the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after buying an additional 1,490 shares during the period. US Bancorp DE lifted its stake in shares of BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after buying an additional 1,528 shares during the period. Finally, 1620 Investment Advisors Inc. lifted its stake in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 675 shares during the period. Institutional investors own 93.24% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Tuesday, May 13th. Wall Street Zen downgraded shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, BioLife Solutions has an average rating of "Moderate Buy" and an average price target of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.